Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) Cash & Equivalents (2018 - 2019)

Historic Cash & Equivalents for DiaMedica Therapeutics (DMAC) over the last 2 years, with Q3 2019 value amounting to $4.7 million.

  • DiaMedica Therapeutics' Cash & Equivalents rose 2162.65% to $4.7 million in Q3 2019 from the same period last year, while for Sep 2019 it was $4.7 million, marking a year-over-year increase of 2162.65%. This contributed to the annual value of $16.8 million for FY2018, which is N/A changed from last year.
  • Per DiaMedica Therapeutics' latest filing, its Cash & Equivalents stood at $4.7 million for Q3 2019, which was up 2162.65% from $3.0 million recorded in Q2 2019.
  • DiaMedica Therapeutics' 5-year Cash & Equivalents high stood at $16.8 million for Q4 2018, and its period low was $2.8 million during Q1 2019.